[L-threo-DOPS therapy and parkinsonism].
Narabayashi
H
H
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000978:Antiparkinson Agents / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D015103:Droxidopa / Q000627:therapeutic use*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D009638:Norepinephrine / Q000378:metabolism; D010300:Parkinson Disease / Q000188:drug therapy* / Q000378:metabolism / Q000601:surgery; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D011725:Pyridines; D012694:Serine / Q000031:analogs & derivatives*; D013238:Stereotaxic Techniques
D000978:Antiparkinson Agents; D011725:Pyridines; D012694:Serine; D007980:Levodopa; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D015103:Droxidopa; D004298:Dopamine; D009638:Norepinephrine